Delivery of host cell-directed therapeutics for intracellular pathogen clearance

References

• Khasnobis S, Escuyer VE, Chatterjee D. Emerging therapeutic targets in tuberculosis: post-genomic era. Expert Opin. Ther. Targets 6(1), 21–40 (2002).
   PubMedGoogle Scholar
• Jaramillo E. Encompassing treatment with prevention: the path for a lasting control of tuberculosis. Soc. Sci. Med. 49(3), 393–404 (1999).
   PubMedGoogle Scholar
• Lawn SD, Zumla AI. Tuberculosis. Lancet 378(9785), 57–72 (2011).
   PubMed Web of Science ®Google Scholar
• Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N. Engl. J. Med. 368(8), 745–755 (2013).
   PubMed Web of Science ®Google Scholar
• Kobets T, Grekov I, Lipoldova M. Leishmaniasis: prevention, parasite detection and treatment. Curr. Med. Chem. 19(10), 1443–1474 (2012).
   PubMed Web of Science ®Google Scholar
• Coburn B, Grassl GA, Finlay BB. Salmonella, the host and disease: a brief review. Immunol. Cell Biol. 85(2), 112–118 (2007).
   PubMed Web of Science ®Google Scholar
• Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull. World Health Organ. 82(5), 346–353 (2004).
   PubMed Web of Science ®Google Scholar
• Maurin M, Raoult D. Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob. Agents Chemother. 45(11), 2977–2986 (2001).
   PubMedGoogle Scholar
• McCafferty DG, Cudic P, Yu MK, Behenna DC, Kruger R. Synergy and duality in peptide antibiotic mechanisms. Curr. Opin. Chem. Biol. 3(6), 672–680 (1999).
   PubMed Web of Science ®Google Scholar
• Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. North Am. 17(3), 615–634 (2003).
   PubMed Web of Science ®Google Scholar
• Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31(4), 1104–1107 (2000).
   PubMed Web of Science ®Google Scholar
• Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol. Biol. Int. 2011, 571242 (2011).
   PubMedGoogle Scholar
• Davies JH. Staphylococcal infection by penicillin-resistant strains. Br. Med. J. 2(4538), 1054 (1947).
   PubMedGoogle Scholar
• Chiu HC, Lee SL, Kapuriya N et al. Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus. Bioorg. Med. Chem. 20(15), 4653–4660 (2012).
   PubMed Web of Science ®Google Scholar
• Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10(12 Suppl.), S122–129 (2004).
   PubMed Web of Science ®Google Scholar
• Costa SS, Ntokou E, Martins A et al. Identification of the plasmid-encoded qacA efflux pump gene in meticillin-resistant Staphylococcus aureus (MRSA) strain HPV107, a representative of the MRSA Iberian clone. Int. J. Antimicrob. Agents 36(6), 557–561 (2010).
   PubMedGoogle Scholar
• Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J. Antimicrob. Chemother. 51(1), 9–11 (2003).
   PubMed Web of Science ®Google Scholar
• Boheim G. Statistical analysis of alamethicin channels in black lipid membranes. J. Membr. Biol. 19(3), 277–303 (1974).
   PubMedGoogle Scholar
• Suh DH, Kim MK, Kim HS, Chung HH, Song YS. Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. Ann. NY Acad. Sci. 1271, 20–32 (2012).
   PubMed Web of Science ®Google Scholar
• Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu. Rev. Biochem. 76, 447–480 (2007).
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499–511 (2004).
   PubMed Web of Science ®Google Scholar
• Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 111(7), 927–930 (2002).
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783–801 (2006).
   PubMed Web of Science ®Google Scholar
• Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J. Leukoc. Biol. 93(6), 847–863 (2013).
   PubMed Web of Science ®Google Scholar
• Bowie A, O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J. Leukoc. Biol. 67(4), 508–514 (2000).
   PubMed Web of Science ®Google Scholar
• Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440(7085), 808–812 (2006).
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17(1), 1–14 (2005).
   PubMed Web of Science ®Google Scholar
• Vuopio-Varkila J, Nurminen M, Pyhala L, Makela PH. Lipopolysaccharide-induced non-specific resistance to systemic Escherichia coli infection in mice. J. Med. Microbiol. 25(3), 197–203 (1988).
   PubMedGoogle Scholar
• Alderson MR, McGowan P, Baldridge JR, Probst P. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res. 12(5), 313–319 (2006).
   PubMedGoogle Scholar
• Thompson BS, Chilton PM, Ward JR, Evans JT, Mitchell TC. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J. Leukoc. Biol. 78(6), 1273–1280 (2005).
   PubMed Web of Science ®Google Scholar
• Kochan T, Singla A, Tosi J, Kumar A. Toll-like receptor 2 ligand pretreatment attenuates retinal microglial inflammatory response but enhances phagocytic activity toward Staphylococcus aureus. Infect. Immun. 80(6), 2076–2088 (2012).
   PubMedGoogle Scholar
• Voltan S, Castagliuolo I, Elli M et al. Aggregating phenotype in Lactobacillus crispatus determines intestinal colonization and TLR2 and TLR4 modulation in murine colonic mucosa. Clin. Vaccine Immunol. 14(9), 1138–1148 (2007).
   PubMedGoogle Scholar
• Nardin EH, Calvo-Calle JM, Oliveira GA et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 166(1), 481–489 (2001).
   PubMedGoogle Scholar
• No authors listed. Mismatched double-stranded RNA: polyI:polyC12U. Drugs R. D. 5(5), 297–304 (2004).
   PubMedGoogle Scholar
• Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 290(5497), 1717–1721 (2000).
   PubMed Web of Science ®Google Scholar
• Byrne BG, Dubuisson JF, Joshi AD, Persson JJ, Swanson MS. Inflammasome components coordinate autophagy and pyroptosis as macrophage responses to infection. MBio 4(1), e00620–00612 (2013).
   PubMed Web of Science ®Google Scholar
• Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors control autophagy. EMBO J. 27(7), 1110–1121 (2008).
   PubMed Web of Science ®Google Scholar
• Chiu HC, Soni S, Kulp SK et al. Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a novel autophagy inducing agent. J. Biomed. Sci. 16, 110 (2009).
   PubMed Web of Science ®Google Scholar
• Chiu HC, Kulp SK, Soni S et al. Eradication of intracellular Salmonella enterica serovar Typhimurium with a small-molecule, host cell-directed agent. Antimicrob. Agents Chemother. 53(12), 5236–5244 (2009).
   PubMed Web of Science ®Google Scholar
• Chiu HC, Yang J, Soni S et al. Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis. Antimicrob. Agents Chemother. 53(7), 2998–3002 (2009).
   PubMedGoogle Scholar
• Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 8( Suppl. 8), 3–9 (2003).
   PubMed Web of Science ®Google Scholar
• Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J. Am. Acad. Dermatol. 43(1 Pt 2), S6–11 (2000).
   Google Scholar
• Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 52, 481–503 (2012).
   PubMed Web of Science ®Google Scholar
• Oyston PC, Fox MA, Richards SJ, Clark GC. Novel peptide therapeutics for treatment of infections. J. Med. Microbiol. 58(Pt 8), 977–987 (2009).
   PubMedGoogle Scholar
• Kanthamneni N, Sharma S, Meenach SA et al. Enhanced stability of horseradish peroxidase encapsulated in acetalated dextran microparticles stored outside cold chain conditions. Int. J. Pharm. 431(1–2), 101–110 (2012).
   PubMedGoogle Scholar
• Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem. Pharmacol. 80(5), 762–770 (2010).
   PubMed Web of Science ®Google Scholar
• Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm. 298(2), 315–322 (2005).
   PubMed Web of Science ®Google Scholar
• Hirota K, Hasegawa T, Hinata H et al. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J. Control. Release 119(1), 69–76 (2007).
   PubMed Web of Science ®Google Scholar
• Hrkach J, Von Hoff D, Mukkaram Ali M et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4(128), 128ra139 (2012).
   PubMedGoogle Scholar
• Service RF. Nanotechnology. Nanoparticle Trojan horses gallop from the lab into the clinic. Science 330(6002), 314–315 (2010).
   PubMed Web of Science ®Google Scholar
• Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41(7), 2971–3010 (2012).
   PubMed Web of Science ®Google Scholar
• US Environmental Protection Agency. Methylene Chloride (Dichloromethane). Technology Transfer Network Air Toxics Web Site (2000).
   Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70(1–2), 1–20 (2001).
   PubMed Web of Science ®Google Scholar
• Baras B, Benoit MA, Gillard J. Influence of various technological parameters on the preparation of spray-dried poly(epsilon-caprolactone) microparticles containing a model antigen. J. Microencapsul. 17(4), 485–498 (2000).
   PubMedGoogle Scholar
• Varshosaz J, Ahmadi F, Emami J et al. Microencapsulation of budesonide with dextran by spray drying technique for colon-targeted delivery: an in vitro/in vivo evaluation in induced colitis in rat. J. Microencapsul. 28(1), 62–73 (2011).
   PubMed Web of Science ®Google Scholar
• Nounou MM, El-Khordagui LK, Khalafallah N. Release stability of 5-fluorouracil liposomal concentrates, gels and lyophilized powder. Acta poloniae pharmaceutica. 62(5), 381–391 (2005).
   PubMedGoogle Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 1(3), 297–315 (2006).
   PubMed Web of Science ®Google Scholar
• Filipovic-Grcic J, Skalko-Basnet N, Jalsenjak I. Mucoadhesive chitosan-coated liposomes: characteristics and stability. J. Microencapsul. 18(1), 3–12 (2001).
   PubMed Web of Science ®Google Scholar
• Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6(5), 1949–1957 (2000).
   PubMed Web of Science ®Google Scholar
• Lu L, Peter SJ, Lyman MD et al. In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams. Biomaterials 21(18), 1837–1845 (2000).
   PubMed Web of Science ®Google Scholar
• Bachelder EM, Beaudette TT, Broaders KE, Dashe J, Frechet JM. Acetal-derivatized dextran: an acid-responsive biodegradable material for therapeutic applications. J. Am. Chem. Soc. 130(32), 10494–10495 (2008).
   PubMed Web of Science ®Google Scholar
• Broaders KE, Cohen JA, Beaudette TT, Bachelder EM, Frechet JM. Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proc. Natl Acad. Sci. USA 106(14), 5497–5502 (2009).
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91(3), 295–298 (1997).
   PubMed Web of Science ®Google Scholar
• Meyer T, Surber C, French LE, Stockfleth E. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin. Investig. Drugs 22(1), 149–159 (2013).
   PubMed Web of Science ®Google Scholar
• Drake MG, Kaufman EH, Fryer AD, Jacoby DB. The therapeutic potential of Toll-like receptor 7 stimulation in asthma. Inflamm. Allergy Drug Targets 11(6), 484–491 (2012).
   PubMedGoogle Scholar
• Weberschock T, Strametz R, Lorenz M et al. Interventions for mycosis fungoides. Cochrane Database Syst. Rev. 9, CD008946 (2012).
   Google Scholar
• Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med. Infect. Dis. 5(3), 150–158 (2007).
   PubMedGoogle Scholar
• Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J. Antimicrob. Chemother. 48(6), 751–755 (2001).
   PubMed Web of Science ®Google Scholar
• Chollet JL, Jozwiakowski MJ, Phares KR et al. Development of a topically active imiquimod formulation. Pharm. Dev. Technol. 4(1), 35–43 (1999).
   PubMed Web of Science ®Google Scholar
• Kono T, Kondo S, Pastore S et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res. 13(2), 71–76 (1994).
   PubMedGoogle Scholar
• Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 27(2), 190–199 (2008).
   PubMed Web of Science ®Google Scholar
• Bachelder EM, Beaudette TT, Broaders KE et al. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol. Pharm. 7(3), 826–835 (2010).
   PubMed Web of Science ®Google Scholar
• Homhuan A. Maturation of dendritic cells induced by nano-liposomes containing imiquimod. Asian Biomedicine 2(3), 233–239 (2008).
   Google Scholar
• Duong AD, Sharma S, Peine KJ et al. Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis. Mol. Pharm. 10(3), 1045–1055 (2013).
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv. Drug Deliv. Rev. 60(7), 805–812 (2008).
   PubMed Web of Science ®Google Scholar
• Pyles RB, Jezek GE, Eaves-Pyles TD. Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect. Immun. 78(4), 1700–1710 (2010).
   PubMedGoogle Scholar
• Parker D, Prince A. Immunopathogenesis of Staphylococcus aureus pulmonary infection. Semin. Immunopathol. 34(2), 281–297 (2012).
   PubMed Web of Science ®Google Scholar
• Seya T, Matsumoto M. The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer. Cancer Immunol. Immunother. 58(8), 1175–1184 (2009).
   PubMedGoogle Scholar
• Lang KS, Recher M, Junt T et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11(2), 138–145 (2005).
   PubMed Web of Science ®Google Scholar
• Smole A, Krajnik AK, Oblak A, Pirher N, Jerala R. Delivery system for the enhanced efficiency of immunostimulatory nucleic acids. Innate. Immun. 19(1), 53–65 (2013).
   PubMedGoogle Scholar
• Peine K, Bachelder EM, Vangundy Z et al. Efficient delivery of the TLR-agonists poly I:C and CpG to macrophages by acetalated dextran microparticles. Mol. Pharmaceutics 10(8), 2849–2857 (2013).
   PubMedGoogle Scholar
• Ballarin-Gonzalez B, Howard KA. Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions. Adv. Drug Deliv. Rev. 64(15), 1717–1729 (2012).
   PubMed Web of Science ®Google Scholar
• Rutz M, Metzger J, Gellert T et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 34(9), 2541–2550 (2004).
   PubMed Web of Science ®Google Scholar
• Milas L, Mason KA, Ariga H et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 64(15), 5074–5077 (2004).
   PubMed Web of Science ®Google Scholar
• Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv. Drug Deliv. Rev. 61(3), 256–262 (2009).
   PubMed Web of Science ®Google Scholar
• Sane SA, Shakya N, Haq W, Gupta S. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis. J. Antimicrob. Chemother. 65(7), 1448–1454 (2010).
   PubMed Web of Science ®Google Scholar
• Kwant A, Rosenthal KL. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 22(23–24), 3098–3104 (2004).
   PubMed Web of Science ®Google Scholar
• Heikenwalder M, Polymenidou M, Junt T et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10(2), 187–192 (2004).
   PubMed Web of Science ®Google Scholar
• Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. 164(11), 5683–5688 (2000).
   PubMedGoogle Scholar
• Golali E, Jaafari MR, Khamesipour A, Abbasi A, Saberi Z, Badiee A. Comparison of in vivo adjuvanticity of liposomal PO CpG ODN with liposomal PS CpG ODN: soluble leishmania antigens as a model. Iran J. Basic Med. Sci. 15(5), 1032–1045 (2012).
   PubMedGoogle Scholar
• Manoharan Y, Ji Q, Yamazaki T et al. Effect of molecular weight of polyethyleneimine on loading of CpG oligodeoxynucleotides onto flake-shell silica nanoparticles for enhanced TLR9-mediated induction of interferon-alpha. Int. J. Nanomedicine 7, 3625–3635 (2012).
   PubMed Web of Science ®Google Scholar
• Das S, Roy P, Mondal S, Bera T, Mukherjee A. One pot synthesis of gold nanoparticles and application in chemotherapy of wild and resistant type visceral leishmaniasis. Colloids Surf. B Biointerfaces 107, 27–34 (2013).
   PubMed Web of Science ®Google Scholar
• Hutson S. Half-century-old TB drugs get a facelift in new cocktails. Nat. Med. 16(12), 1346 (2010).
   PubMedGoogle Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10(2), 417–426 (2002).
   PubMed Web of Science ®Google Scholar
• von Moltke J, Ayres JS, Kofoed EM, Chavarria-Smith J, Vance RE. Recognition of bacteria by inflammasomes. Annu. Rev. Immunol. 31, 73–106 (2013).
   PubMed Web of Science ®Google Scholar
• Puri N, Weyand EH, Abdel-Rahman SM, Sinko PJ. An investigation of the intradermal route as an effective means of immunization for microparticulate vaccine delivery systems. Vaccine 18(23), 2600–2612 (2000).
   PubMedGoogle Scholar
• Bal SM, Slutter B, Verheul R, Bouwstra JA, Jiskoot W. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice. Eur. J. Pharm. Sci. 45(4), 475–481 (2012).
   PubMed Web of Science ®Google Scholar
• Wischke C, Mathew S, Roch T, Frentsch M, Lendlein A. Potential of NOD receptor ligands as immunomodulators in particulate vaccine carriers. J. Control. Release 164(3), 299–306 (2012).
   PubMed Web of Science ®Google Scholar
• Di Virgilio F. The therapeutic potential of modifying inflammasomes and NOD-like receptors. Pharmacol. Rev. 65(3), 872–905 (2013).
   PubMed Web of Science ®Google Scholar
• Valdivia-Arenas M, Amer A, Henning L, Wewers M, Schlesinger L. Lung infections and innate host defense. Drug Discov. Today Dis. Mech. 4(2), 73–81 (2007).
   PubMedGoogle Scholar
• Kuhlman M, Joiner K, Ezekowitz RA. The human mannose-binding protein functions as an opsonin. J. Exp. Med. 169(5), 1733–1745 (1989).
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann. NY Acad. Sci. 1143, 1–20 (2008).
   PubMed Web of Science ®Google Scholar
• Miranda-Verastegui C, Tulliano G, Gyorkos TW et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl. Trop. Dis. 3(7), e491 (2009).
   PubMed Web of Science ®Google Scholar
• Arevalo I, Ward B, Miller R et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33(11), 1847–1851 (2001).
   PubMed Web of Science ®Google Scholar
• Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 24(10), 1211–1217 (2006).
   PubMed Web of Science ®Google Scholar
• Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9(1), 1–14 (2013).
   PubMed Web of Science ®Google Scholar
• Sheridan C. Proof of concept for next-generation nanoparticle drugs in humans. Nat. Biotechnol. 30(6), 471–473 (2012).
   PubMed Web of Science ®Google Scholar
• BBC Research. Nanotechnology in medical applications: the global market. BBC Market Forcasting, January (2012).
   Google Scholar
• Heit A, Schmitz F, Haas T, Busch DH, Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur. J. Immunol. 37(8), 2063–2074 (2007).
   PubMed Web of Science ®Google Scholar
• Boghdadi G, Khalik DA, Wahab SA, Farghaly A. Immunomodulatory effect of R848 on cytokine production associated with Schistosoma mansoni infection. Parasitol. Res. 112(1), 135–140 (2013).
   PubMedGoogle Scholar
• Halperin SA, Dobson S, McNeil S et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 24(1), 20–26 (2006).
   PubMed Web of Science ®Google Scholar
• Demento SL, Bonafe N, Cui W et al. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J. Immunol. 185(5), 2989–2997 (2010).
   PubMed Web of Science ®Google Scholar
• Stone GW, Barzee S, Snarsky V et al. Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like R eceptor agonists as a treatment for melanoma. PLoS ONE 4(10), e7334 (2009).
   Google Scholar
• Ichinohe T, Watanabe I, Ito S et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79(5), 2910–2919 (2005).
   PubMed Web of Science ®Google Scholar
• Wischke C, Zimmermann J, Wessinger B et al. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int. J. Pharm. 365(1–2), 61–68 (2009).
   PubMed Web of Science ®Google Scholar
• Heuking S, Adam-Malpel S, Sublet E, Iannitelli A, Stefano A, Borchard G. Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. J. Drug Target 17(8), 662–670 (2009).
   PubMed Web of Science ®Google Scholar
• Borchard G, Primard C. Adjuvant Effect of Plga Nanocarrier Vectorizing One or Two Tlr Agonists, Administered by Nasal Route. University of Geneva, University of Lausanne, Geneva, CH (2011).
   Google Scholar
• Boland G, Beran J, Lievens M et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23(3), 316–320 (2004).
   PubMedGoogle Scholar
• Buckland KF, Ramaprakash H, Murray LA et al. Triggering receptor expressed on myeloid cells-1 (TREM-1) modulates immune responses to Aspergillus fumigatus during fungal asthma in mice. Immunol. Invest. 40(7–8), 692–722 (2011).
   PubMed Web of Science ®Google Scholar
• Kazzaz J, Singh M, Ugozzoli M, Chesko J, Soenawan E, O’Hagan DT. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J. Control. Release 110(3), 566–573 (2006).
   PubMed Web of Science ®Google Scholar
• Chong CS, Cao M, Wong WW et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J. Control. Release 102(1), 85–99 (2005).
   PubMed Web of Science ®Google Scholar
• Huleatt JW, Nakaar V, Desai P et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26(2), 201–214 (2008).
   PubMed Web of Science ®Google Scholar